PATH | VRL
Menu

Find resources

Total results with these characteristics: 212

Disease: Pneumococcus

Page 3 of 11
Efficacy of a Novel, Protein-Based Pneumococcal Vaccine Against Nasopharyngeal Carriage of Streptococcus pneumoniae in Infants: A Phase 2, Randomized, Controlled, Observer-Blind Study

This article, published in Vaccine, assessed the efficacy of two formulations of a pneumococcal vaccine candidate against nasopharyngeal carriage (NPC) prevalence in infants in The Gambia. It examined the impact of the two vaccine formulations on …

Author: Odutola A, Ota MOC, Antonio M, et al.

Publication date: 2017

Efficacy of a Pneumococcal Conjugate Vaccine Against Acute Otitis Media

This study, published in the New England Journal of Medicine, enrolled 1662 infants in a randomized, double-blind efficacy trial of a heptavalent pneumococcal polysaccharide conjugate vaccine in which the carrier protein is the nontoxic …

Author: Eskola J, Kilpi T, Palmu A, et al.

Publication date: 2001

Efficacy of Pneumococcal Conjugate Vaccines and Their Effort on Carriage and Antimicrobial Resistance

Pneumococcal conjugate vaccines have shown a high degree of success in preventing pneumococcal bacteraemia in children. They also reduce the acquisition of carriage of vaccine serotypes in the nasopharynx, and reduce otitis media caused by those …

Author: Klugman K

Publication date: 2001

Ending Preventable Child Deaths From Pneumonia and Diarrhoea by 2025 – The Integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)

This report proposes a cohesive approach to ending preventable pneumonia and diarrhea deaths in children. It outlines a protect, prevent, and treat framework that integrates proven effective interventions for pneumonia and diarrhea, including the …

Author: World Health Organization, United Nations Children's Fund

Publication date: 2013

Epidemiology, Aetiology and Management of Childhood Acute Community-Acquired Pneumonia in Developing Countries--A Review

This article, published in the African Journal of Medicine and Medical Sciences, provides an overview of the causes of clinical pneumonia in developing countries, available vaccines for fighting pneumonia, and efforts underway and planned to expand …

Author: Falade AG, Ayede AI

Publication date: 2011

Establishment of a New Human Pneumococcal Standard Reference Serum 007sp

This article, published in Clinical and Vaccine Immunology, reports on a study that resulted in the development of a new pneumococcal reference serum to replace the dwindling stocks of Lot 89SF, the reference standard serum pool used since 1990. The …

Author: Goldblatt D, Plikaytis BD, Akkoyunlu M, et al.

Publication date: 2011

Estimated Hib and Pneumococcal Deaths for Children Under 5 Years of Age, 2008

This web page provides an estimate of child mortality due to Haemophilus influenzae type b (Hib) and pneumococcal infections in 2008. It also contains a link to a chart of death rates due to these infections, broken down by region and HIV status.

Author: World Health Organization

Publication date: 2013

Estimates of World-Wide Distribution of Child Deaths From Acute Respiratory Infections

To establish a relation between deaths due to acute respiratory infections (ARI) and all-cause deaths in children under 5 years we show that the proportion of deaths directly attributable to ARI declines from 23% to 18% and then 15% (95% confidence …

Author: Williams B, Gouws E, Boschi-Pinto C, Bryce J, Dye C

Publication date: 2002

Estimating the Burden of Pneumococcal Pneumonia Among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques

This article, published in PLOS One, summarizes a study to develop a conceptual and quantitative strategy for estimating the non-bacteremic disease burden among adults with community-acquired pneumonia. The authors conclude that the adult burden of …

Author: Said MA, Johnson HL, Nonyane BAS, Deloria-Knoll M, O′Brien KL

Publication date: 2013

Estimating the Protective Concentration of Anti-pneumococcal Capsular Polysaccharide Antibodies

Published in the journal Vaccine, this article describes a method for correlating pneumococcal anticapsular antibody responses of infants immunized with pneumococcal conjugate (PnC) vaccine (Prevenar) with clinical protection from invasive …

Author: Siber G, Chang I, Baker S, et al.

Publication date: 2007

The Evidence Base for Pneumococcal Conjugate Vaccines (PCVs): Data for Decision-Making Around PCV Use in Childhood

This report provides the latest information on pneumococcal conjugate vaccines (PCV) and their use in routine immunization programs around the world. It includes key background on the burden of pneumococcal disease in children and the impact of PCVs …

Author: International Vaccine Access Center

Publication date: 2017

The Evidence for Using Conjugate Vaccines to Protect HIV-Infected Children Against Pneumococcal Disease

Published in The Lancet, this review summarises available data on the burden of pneumococcal disease and the safety and efficacy of PCVs in HIV-infected children. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to …

Author: Bliss SJ, O'Brien KL, Janoff EN, et al.

Publication date: 2008

Evolution of Streptococcus Pneumoniae Serotypes and Penicillin Susceptibility in Latin America, Sireva-Vigia Group, 1993-1999

Since 1993 the Pan American Health Organization has coordinated a surveillance network with the National Reference Laboratories of Argentina, Brazil, Chile, Colombia, Mexico and Uruguay aimed at monitoring capsular types and antimicrobial …

Author: Di Fabio JL, Castañeda E, Agudelo CI, et al.

Publication date: 2001

Expanding the Evidence Base to Inform Vaccine Introduction: Program Costing and Cost-Effectiveness Analyses

This supplement to Vaccine contains 38 articles featuring country-led research to support real-time policymaking, including cost-effectiveness, program costing, and analyses of financial flows for vaccine introduction. It highlights work undertaken …

Author: Andrus JK, Walker DG, eds.

Publication date: 2015

Exploitation of Physiology and Metabolomics to Identify Pneumococcal Vaccine Candidates

This article, published in Expert Review of Vaccines, summarizes ways in which genome-wide techniques can help decipher factors associated with the fitness, metabolism, and virulence of Streptococcus pneumoniae that could help lead to the …

Author: Schulz C, Hammerschmidt S

Publication date: 2013

Formulation of a Killed Whole Cell Pneumococcus Vaccine—Effect of Aluminum Adjuvants on the Antibody and IL-17 Response

This article, published in the Journal of Immune Based Therapies and Vaccines, describes preclinical research which demonstrates that a vaccine composed of killed whole cell, nonencapsulated pneumococci and formulated with aluminum hydroxide induces …

Author: HogenEsch H, Dunham A, Hansen B, Anderson K, Maisonneuve JF, Hem SL

Publication date: 2011

The Fundamental Link Between Pneumococcal Carriage and Disease

This article, published Expert Review of Vaccines, reviews the evidence supporting pneumococcal carriage as an immediate and necessary precursor to pneumococcal disease. The authors emphasize the role of information on pneumococcal carriage in …

Author: Simell B, Auranen K, Käyhty H, et al.

Publication date: 2012

The Future of Pneumococcal Disease Prevention

This article, published in Vaccine, reviews the most recently developed pneumococcal conjugate vaccines (PCVs) that are now approved for use in children, a 10-valent vaccine and a 13-valent vaccine, as well as other new PCVs in development. In view …

Author: Rodgers GL, Klugman KP

Publication date: 2011

The Gavi Full Country Evaluations

The Gavi Full Country Evaluations (FCE) are prospective studies that aim to understand and quantify the barriers and drivers of immunization program improvement, with an emphasis on the contribution of Gavi, the Vaccine Alliance in four countries: …

Author: PATH

GAVI's Advance Market Commitment

This article, published in The Lancet, details how the GAVI Alliance's pilot Advance Market Commitment financing mechanism works to stimulate the manufacture of affordable pneumococcal vaccines for developing countries. ABSTRACT ONLY. (Learn how …

Author: Schwalbe N, El-Ziq I

Publication date: 2010

Page 3 of 11